RTT Premium Stocks

Home
United States
Washington D.C., DC
RTT Premium Stocks

RTT Biotech Investor and RTT Intelligent Investor services give subscribers the edge to make more successful investments. Welcome to RTTNews Premium stocks.

For over 20 years, RTTNews has been providing news and analysis from around the globe that can impact individual stocks and broader markets to leading banks, brokerages and hedge funds. Now RTT is offering the same information to individual investors and traders. RTT Premium Stocks consists of RTT Biotech Investor and RTT Intelligent Investor

RTT Biotech Investor - Biotech investment is one of the exciting spaces in the stock market. The companies in this sector focus on clinical research and development of new drugs. There is tremendous potential for stocks to deliver outstanding gains when companies report positive trial data or when their drugs obtain FDA approval. At RTTNews, a dedicated team tracks these companies and developments. As a subscriber, you will have access to all the timely news, time-sensitive information, and alerts that can enable you to make sound investment decisions. RTT Intelligent Investor - is your all-encompassing guide to profitable investment decisions. The daily newsletter filters through though mounds of data to provide timely and valuable information to subscribers. Our premium alerts identify stocks with upside potential, handpicked after meticulous research and analysis to help you benefit from the stock market in the next few days/weeks/months. Our premium services give subscribers the edge they need to make more successful investments and trades by discovering opportunities long before they catch the attention of mainstream investors. Our stocks have consistently and significantly outperformed the broader markets. Unlike other services that highlight a few top gainers, we provide a complete performance table for all the stocks we publish, so you can see the true performance of the service at any given time. By incorporating our research into your trading strategy, you can find the best trading opportunities every day. Let our experts provide you with timely insight and analysis, so you can focus on your investment strategies. Along with our in-depth research and concise reports, we also provide technical analysis that identify key support/resistance levels, stock trends, chart patterns and other key indicators when applicable. Sign up today for your RISK-FREE 7 day trial, and let us help you find the best investment and trading opportunities.

05/23/2025

𝗣𝗥𝗘 𝗦𝗼𝗮𝗿𝘀 𝗢𝘃𝗲𝗿 𝟳𝟬% 𝗜𝗻 𝗝𝘂𝘀𝘁 𝗧𝗵𝗿𝗲𝗲 𝗗𝗮𝘆𝘀, 𝗩𝗜𝗚𝗟 𝗦𝗻𝗮𝗽𝗽𝗲𝗱 𝗨𝗽, 𝗜𝗥𝗧𝗖 𝗙𝗶𝗻𝗱𝘀 𝗜𝘁𝘀 𝗥𝗵𝘆𝘁𝗵𝗺 𝗔𝗴𝗮𝗶𝗻...

"Have patience. Stocks don't go up immediately," said American investor Walter Schloss. While many stocks reward investors after being held with long-term conviction, a few can deliver impressive gains in a short span. The following stocks hit new 52-week highs yesterday. Were they a part of your portfolio?

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

01/09/2025

𝗙𝗿𝗼𝗺 𝗔𝗹𝗲𝗿𝘁 𝘁𝗼 𝗔𝗹𝗹-𝗧𝗶𝗺𝗲 𝗛𝗶𝗴𝗵: 𝗔𝗠𝗦𝗖'𝘀 𝟳𝟰.𝟰% 𝗝𝘂𝗺𝗽 𝗶𝗻 𝟯𝟴 𝗗𝗮𝘆𝘀

We alerted our premium subscribers to American Superconductor Corp. (AMSC) stock on September 20, 2024, when it was trading at around $21.80. By November 13, 2024, this power technologies stock reached an all-time high of $38.02, marking an impressive 74.4% increase from our published price.

Click Below 👇 to Subscribe to RTT Intelligent Investor & read this report

https://bit.ly/30kAY7q

‘Intelligent Investor’ is your all-encompassing guide to profitable investment decisions. The daily newsletter filters through mounds of data to provide timely and valuable information to subscribers. Our premium alerts identify stocks with upside po

06/05/2024

𝗗𝗶𝗱 𝗬𝗼𝘂 𝗣𝗶𝗰𝗸 𝗨𝗽 𝗣𝗜 𝗕𝗲𝗳𝗼𝗿𝗲 𝗜𝘁 𝗚𝗮𝗶𝗻𝗲𝗱 𝟴𝟵%?

RFID maker Impinj Inc. (PI), was featured on our 'Short-Term Investor' on January 17, 2024, when it was trading at around $92.45. On May 16, 2024, the stock reached an all-time high of $175.41, representing a gain of 89.7% from our published price.

Click Below 👇 to Subscribe to RTT Intelligent Investor & read this report

https://bit.ly/30kAY7q

05/20/2024

𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗦𝘁𝗼𝗰𝗸 𝘄𝗶𝘁𝗵 𝟰𝟴.𝟴% 𝗥𝗲𝘁𝘂𝗿𝗻 𝗶𝗻 𝗝𝘂𝘀𝘁 𝟯𝟲 𝗗𝗮𝘆𝘀 - 𝗗𝗼 𝗬𝗼𝘂 𝗢𝘄𝗻?

We alerted our premium subscribers to NovoCure Ltd. (NVCR) stock on March 27, 2024, when it was trading at around $14.99. Subsequently, on May 17, 2024, this oncology stock reached an intra-day high of $22.31, signifying a notable increase of 48.8% from our published price.

Click Below 👇 to Subscribe to RTT Intelligent Investor & read this report

https://bit.ly/30kAY7q

05/13/2024

𝗔𝗳𝘁𝗲𝗿 𝗶𝗺𝗽𝗿𝗲𝘀𝘀𝗶𝘃𝗲 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀, 𝗔𝗗𝗠𝗔 𝗦𝗲𝘁𝘀 𝘁𝗵𝗲 𝗕𝗮𝗿 𝗛𝗶𝗴𝗵 𝗳𝗼𝗿 𝟮𝟬𝟮𝟰

ADMA Biologics, Inc. (ADMA), which delivered strong Q1 results, has revised up its guidance for 2024 again. On Feb.15, 2024, we featured ADMA on our site when it was trading around $5. The stock touched a 52-week high of $9.02 last week (May 10), before closing at $8.81.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

05/10/2024

𝗥𝗮𝗱𝗡𝗲𝘁 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘀 𝗧𝗿𝗶𝗽𝗹𝗲 𝗗𝗶𝗴𝗶𝘁 𝗚𝗮𝗶𝗻𝘀 𝗜𝗻 𝗮 𝗟𝗶𝘁𝘁𝗹𝗲 𝗢𝘃𝗲𝗿 𝗔 𝗬𝗲𝗮𝗿

After a banner year in 2023, RadNet Inc. (RDNT) has revised up its revenue outlook for 2024, thanks to the positive trends being experienced in virtually all aspects of its business and the strong financial performance of the first quarter. The company now expects revenue for the year to range between $1,675 million to $1,725 million, up from its prior outlook range of $1,650 million to $1,700 million. The total net revenue reported last year was $1,604.2 million.

We alerted readers to RDNT on Mar.1, 2023, when it was trading around $23.47. The stock closed at an all-time high of $53.57 yesterday, reflecting a gain of more than 120% in a little over a year.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

05/06/2024

𝗗𝗶𝗱 𝗥𝗫𝗦𝗧 𝗦𝗵𝗶𝗻𝗲 𝗕𝗿𝗶𝗴𝗵𝘁 𝗜𝗻 𝗬𝗼𝘂𝗿 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼?

Shares of RxSight Inc. (RXST), an ophthalmic medical device company, touched an all-time high of $61.85 last week. The company markets FDA-approved proprietary RxSight Light Adjustable Lens system, the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.

The financial results for the first quarter of 2024 are scheduled to be reported today after the market close, i.e., May 6, 2024.

We featured RXST on our site on Aug.10, 2022, when it was trading around $15.45 and again on July 10, 2023, when it was trading around $31.30. If you had purchased the stock in August 2022, you would now be enjoying substantial returns, with gains of 300%.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

05/02/2024

𝗣𝗥𝗢𝗖𝗘𝗣𝗧 𝗕𝗶𝗼𝗥𝗼𝗯𝗼𝘁𝗶𝗰𝘀’ 𝗠𝗲𝘁𝗲𝗼𝗿𝗶𝗰 𝗥𝗶𝘀𝗲 𝗖𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝘀…

After a stellar performance in 2023, PROCEPT BioRobotics Corp. (PRCT) has kicked off 2024 with resounding revenue growth in the first quarter, setting the stage for a thrilling journey ahead. With growing demand for its products, the company has revised up its revenue outlook for this year.

PRCT was featured on our site on June 27, 2022, when it was trading around $33. The stock rallied in the successive days and touched an intraday high of $52.40 on September 9, 2022. We revisited the stock on July 28, 2023, when it had given back all its earlier gains and was trading around $35. Yesterday, however, marked a historic milestone as PRCT closed at an all-time high of $60.61.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

04/11/2024

𝗗𝗶𝗱 𝗔𝗹𝗽𝗶𝗻𝗲 𝗔𝗱𝗱 𝗦𝗼𝗺𝗲 𝗦𝗵𝗶𝗻𝗲 𝗧𝗼 𝗬𝗼𝘂𝗿 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼?

Alpine Immune Sciences Inc. (ALPN) has agreed to be acquired by Vertex Pharmaceuticals Inc. (VRTX) for $65 per share or roughly $4.9 billion in cash.

The lead drug candidate of Alpine is Povetacicept, which has demonstrated efficacy in IgA nephropathy through phase II development. Povetacicept is on track to advance into phase III trial in the second half of 2024.

We alerted readers to Alpine on Mar.3, 2023, when it was trading around $7.97. The offer price of $65 per share reflects a gain of 715% in just over a year.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

04/01/2024

𝗖𝗲𝗹𝗰𝘂𝗶𝘁𝘆 𝗦𝗸𝘆𝗿𝗼𝗰𝗸𝗲𝘁𝘀 𝟭𝟯𝟯% 𝗶𝗻 𝟲.𝟱 𝗠𝗼𝗻𝘁𝗵𝘀, 𝗩𝗜𝗞𝗧𝗢𝗥𝗜𝗔-𝟭 𝗗𝗮𝘁𝗮 𝗼𝗻 𝗗𝗲𝗰𝗸

Celcuity Inc. (CELC), having advanced its lead drug candidate Gedatolisib and strengthened its balance sheet in 2023, remains on track for a data readout this year.

A phase III study, dubbed VIKTORIA-1, evaluating Gedatolisib plus Fulvestrant with and without Palbociclib for the treatment of patients with PIK3CA-mutated or wild-type hormone receptor (HR)-positive/HER2-negative breast cancer who have previously progressed on first-line therapy with a CDK4/6 inhibitor and a non-steroidal aromatase inhibitor is underway.

Topline results from the PI3KCA wild-type patient subgroup of the VIKTORIA-1 trial are projected to be released in the second half of 2024, while data from the PIK3CA mutant patient subgroup is expected to be available in the first half of 2025.

CELC was featured on our site on Sep.14, 2023, when it was trading around $9.52. The stock touched a 52-week high of $22.19 during intraday trading on Mar.28, 2024, marking a significant increase of 133% in 6.5 months.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

03/26/2024

𝗟𝗮𝗻𝗱𝗼𝘀 𝗦𝗸𝘆𝗿𝗼𝗰𝗸𝗲𝘁𝘀 - 𝗪𝗲𝗿𝗲 𝗬𝗼𝘂 𝗢𝗻 𝗕𝗼𝗮𝗿𝗱?

Landos Biopharma Inc. (LABP), a clinical stage biopharmaceutical company developing novel, oral therapeutics for autoimmune diseases, has agreed to be acquired by AbbVie Inc. (ABBV).

As per the terms of the deal, Landos will be acquired for $20.42 per share in cash upon closing, or about $137.5 million in the aggregate. Additionally, shareholders of Landos will receive one non-tradable contingent value right per share potentially adding up to $11.14 per share, or an extra $75 million collectively, contingent upon the attainment of a clinical development milestone.

We alerted readers to LABP on Jan.30, 2024, when it was trading around $5.05. The stock closed yesterday’s trading at $21.40, marking an impressive gain of over 320% in less than two months.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

03/21/2024

𝗖𝗲𝗿𝘃𝗼𝗠𝗲𝗱 𝗮𝘁 𝟱𝟮-𝘄𝗲𝗲𝗸 𝗵𝗶𝗴𝗵. 𝗗𝗼 𝘆𝗼𝘂 𝗿𝗲𝗺𝗲𝗺𝗯𝗲𝗿 𝘁𝗵𝗶𝘀 𝗮𝗿𝘁𝗶𝗰𝗹𝗲?

CervoMed Inc. (CRVO), which is developing a drug for Dementia with Lewy Bodies, or DLB, touched a 52-week high of $26.38 during intraday trading yesterday, before closing at $25.93.

The company’s lead drug candidate is Neflamapimod, which is currently under a phase IIb clinical trial in dementia with Lewy bodies, dubbed RewinD-LB. This study remains on track to complete enrollment in the first half of 2024, with primary efficacy results expected in the second half of 2024.

We alerted readers to CRVO on Feb.12, 2024, when it was trading around $11.61 (Report titled “Remember To Keep An Eye On CervoMed Stock”). Yesterday’s intraday high of $26.38 marks a notable increase of over 125% in less than 2 months.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T

RTT Biotech Investor offers useful resources like Daily Biotech News,Clinical Trial Catalysts,Premium FDA Calendar & more that is helpful for trading or investing in Biotech & Pharma stocks.

Address

Washington D.C., DC

Telephone

+12027694900

Website

https://www.rttnews.com/products/biotechinvestor.aspx

Alerts

Be the first to know and let us send you an email when RTT Premium Stocks posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Washington D.C.?